血浆白细胞介素-18升高识别传统炎症细胞因子潜在类别分析未能区分的高危急性呼吸窘迫综合征患者:两项随机临床试验的回顾性分析
该研究为SAILS和HARP-2两项多中心随机对照试验的二次分析,共纳入SAILS 683例和HARP-2 511例ARDS患者。33%的患者IL-18水平与LCA分类不一致,IL-18与LCA所用细胞因子仅轻度相关(0.17-0.47)。在LCA分类为低炎症的患者中,14%的SAILS和43%的HARP-2患者IL-18升高(≥800 pg/mL),这些患者60天死亡风险显著升高:SAILS中42%死亡(OR 3.3; 95%CI 1.8-6.1; p<0.001),HARP-2中27%死亡(OR 2.1; 95%CI 1.2-3.8; p=0.009)。结论认为血浆IL-18水平为传统炎症生物标志物定义的LCA亚表型提供了重要的附加预后信息。
要点
- 在SAILS和HARP-2两项ARDS试验中,33%的患者IL-18水平与LCA分类不一致,提示两种分类识别不同高危人群。
- LCA分类为低炎症但IL-18≥800 pg/mL的患者60天死亡风险显著升高:SAILS中OR 3.3(95%CI 1.8-6.1; p<0.001),HARP-2中OR 2.1(95%CI 1.2-3.8; p=0.009)。
- LCA低炎症组中IL-18升高的比例分别为SAILS 14%和HARP-2 43%,提示传统LCA可能漏判部分高危患者。
- IL-18与LCA所用细胞因子仅轻度相关(0.17-0.47),支持IL-18反映炎症小体激活这一潜在不同通路。
适用人群与场景
- SAILS试验纳入683例ARDS患者,HARP-2试验纳入511例ARDS患者,均为多中心随机对照试验人群。
诊断标准与关键阈值
- 高IL-18水平定义为血浆IL-18≥800 pg/mL。
- LCA分类为低炎症(hypoinflammatory)或高炎症,基于传统炎症细胞因子。
研究设计与关键结果
- 研究类型:两项多中心随机对照试验(SAILS和HARP-2)的回顾性二次分析。
- 样本量:SAILS 683例,HARP-2 511例ARDS患者。
- 主要分析:在LCA低炎症组中,IL-18升高与60天死亡率相关:SAILS中42%死亡(OR 3.3; 95%CI 1.8-6.1; p<0.001),HARP-2中27%死亡(OR 2.1; 95%CI 1.2-3.8; p=0.009),校正年龄、APACHE评分和性别。
- 不一致性:33%的患者IL-18水平与LCA分类不一致。
- LCA低炎症组中IL-18升高比例:SAILS 14%,HARP-2 43%。
- 相关性:IL-18与LCA所用细胞因子仅轻度相关(0.17-0.47)。
证据类型、等级与局限
- 证据类型:两项多中心随机对照试验的回顾性二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Interleukin-18 (IL-18) plasma level and latent class analysis (LCA) have separately been shown to predict prognosis and treatment response in acute respiratory distress syndrome (ARDS). IL-18 is a measure of inflammasome activation, a pathway potentially distinct from inflammation captured by biomarkers defining previously published LCA classes. We hypothesized that elevated IL-18 would identify distinct "high-risk" patients not captured by prior LCA classifications.
DESIGN: Statins for acutely injured lungs from sepsis (SAILS) and hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction trial (HARP-2) are two large randomized, controlled trials in ARDS in which both LCA assignments and IL-18 levels were shown to predict mortality. We first evaluated the overlap between high IL-18 levels (≥ 800 pg/mL) with prior LCA class assignments using McNemar's test and then tested the correlation between IL-18 and LCA biomarkers using Pearson's exact test on log-2 transformed values. Our primary analysis was the association of IL-18 level with 60-day mortality in the hypoinflammatory LCA class, which was assessed using the Fisher exact test and Cox proportional hazards modeling adjusting for age, Acute Physiology and Chronic Health Evaluation score, and gender. Secondary analyses included the association of IL-18 and LCA with mortality within each IL-18/LCA subgroup.
SETTING: Secondary analysis of two multicenter, randomized controlled clinical trials of ARDS patients.
SUBJECTS: Six hundred eighty-three patients in SAILS and 511 patients in HARP-2.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We found that 33% of patients in SAILS and HARP-2 were discordant by IL-18 level and LCA class. We further found that IL-18 level was only modestly correlated (0.17-0.47) with cytokines used in the LCA assignment. A substantial subset of individuals classified as hypoinflammatory by LCA (14% of SAILS and 43% of HARP-2) were classified as high risk by elevated IL-18. These individuals were at high risk for mortality in both SAILS (42% 60-d mortality, odds ratio [OR] 3.3; 95% CI, 1.8-6.1; p < 0.001) and HARP-2 (27% 60-d mortality, OR 2.1; 95% CI, 1.2-3.8; p = 0.009).
CONCLUSIONS: Plasma IL-18 level provides important additional prognostic information to LCA subphenotypes defined largely by traditional inflammatory biomarkers in two large ARDS cohorts.
参考来源
- Moore AR, Pienkos SM, Sinha P, et al. Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical Trials. Crit Care Med. 2023. PMID: 37695136. doi:10.1097/CCM.0000000000006028
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。